MDElliottMD: home-claude category backfill (parser-claude gap closure)

2026-05-23T10:43:35Z

home-claude category backfill (parser-claude gap closure)

← Older revision		Revision as of 10:43, 23 May 2026
Line 21:		Line 21:
	== References ==		== References ==
	<references />		<references />
			[[Category:Antiepileptics]]
			[[Category:Mood stabilizers]]
			[[Category:Migraine prophylaxis]]

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #160

2026-05-23T03:56:07Z

parser-claude batch MedTemplate pre-fill, Top 300 #160

New page

{{MedTemplate
| generic = Valproate (valproic acid, divalproex sodium, sodium valproate)
| brand = Depakote, Depakote ER, Depakene, Depacon (IV)
| structure =
| classes = [[:Category:Antiepileptics|Antiepileptic]], [[:Category:Mood_stabilizers|Mood stabilizer]], [[:Category:Migraine_prophylaxis|Migraine prophylaxis]]
| uses = <vote slug="generalized-epilepsy-use">Generalized epilepsy (absence, tonic-clonic, myoclonic)</vote>, <vote slug="focal-epilepsy-use">Focal epilepsy</vote>, <vote slug="bipolar-mania-use">Bipolar disorder (acute mania, maintenance)</vote>, <vote slug="migraine-prophylaxis-use">Migraine prophylaxis</vote>, <vote slug="status-epilepticus-use">Status epilepticus (IV)</vote>
| starting_dose = Seizures: 10-15 mg/kg/d divided BID-TID, titrate to therapeutic level (50-100 mcg/mL); bipolar mania: 750 mg/d divided, titrate
| preparations = 125, 250, 500 mg delayed-release tablets (Depakote); 250, 500 mg ER tablets (Depakote ER); 125, 250 mg sprinkle capsules; 250 mg/5 mL syrup; 500 mg IV (Depacon)
| fda_max = 60 mg/kg/d (typically up to 3000 mg/d)
| pill_id =
| routes = Oral, IV, rectal (off-label use of injection)
| onset = Anticonvulsant effect within days; mood-stabilizing effect 1-3 weeks
| duration = 12 hours (IR); 24 hours (ER)
| halflife = 9-16 hours<ref name="depakote-label">FDA Prescribing Information, Depakote (divalproex sodium), AbbVie, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/018723s063,019680s065,020320s056lbl.pdf</ref>
| bioavailability = ~100% (oral); highly (~90%) protein-bound, with non-linear binding above therapeutic levels (free fraction matters clinically in hypoalbuminemia)<ref name="depakote-label" />
| pregnancy = '''Contraindicated for migraine prophylaxis in pregnancy; high teratogenic risk''' (neural tube defects, craniofacial anomalies, cardiac defects, cognitive/IQ impairment); avoid in women of childbearing potential without reliable contraception when alternatives exist<ref name="depakote-label" />
| legal = [[USLegal:Prescription only|Rx-only]] in US. Carries '''Boxed Warnings''' for hepatotoxicity (especially children <2 with metabolic disorders), teratogenicity, and pancreatitis<ref name="depakote-label" />
| mechanism = <vote slug="valproate-mech-claim">Valproate broadens GABAergic inhibition (raises GABA synthesis, inhibits degradation), blocks voltage-gated sodium channels (slow-inactivated state preference), blocks T-type calcium channels (relevant to absence seizures), and inhibits histone deacetylases (postulated mood-stabilizer mechanism); the multi-mechanism profile underlies the broad-spectrum anticonvulsant activity.</vote> Hyperammonemic encephalopathy (consider in any unexplained CNS depression), thrombocytopenia, and polycystic ovary syndrome are characteristic chronic-use adverse effects beyond hepatic and pancreatic risks<ref name="depakote-label" />.
}}

== References ==
<references />

Valproate - Revision history

MDElliottMD: home-claude category backfill (parser-claude gap closure)

MDElliottMD: parser-claude batch MedTemplate pre-fill, Top 300 #160